Galera Therapeutics GRTX Stock
Galera Therapeutics Price Chart
Galera Therapeutics GRTX Financial and Trading Overview
| Galera Therapeutics stock price | 0.1 USD |
| Previous Close | 0.1 USD |
| Open | 0.1 USD |
| Bid | 0.1 USD x 1000000 |
| Ask | 0.1 USD x 500000 |
| Day's Range | 0.1 - 0.11 USD |
| 52 Week Range | 0.02 - 0.15 USD |
| Volume | 62.03K USD |
| Avg. Volume | 306.38K USD |
| Market Cap | 20.33M USD |
| Beta (5Y Monthly) | 2.642 |
| PE Ratio (TTM) | 0.15625 |
| EPS (TTM) | 0.64 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GRTX Valuation Measures
| Enterprise Value | 14.84M USD |
| Trailing P/E | 0.15625 |
| Forward P/E | -0.08064516 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.8867925 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Galera Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.642 |
| 52-Week Change | 284.61% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.15 USD |
| 52 Week Low | 0.02 USD |
| 50-Day Moving Average | 0.08 USD |
| 200-Day Moving Average | 0.04 USD |
GRTX Share Statistics
| Avg. Volume (3 month) | 306.38K USD |
| Avg. Daily Volume (10-Days) | 68.53K USD |
| Shares Outstanding | 203.27M |
| Float | 70.92M |
| Short Ratio | 1.16 |
| % Held by Insiders | 24.22% |
| % Held by Institutions | 3.70% |
| Shares Short | 2.12M |
| Short % of Float | 5.28% |
| Short % of Shares Outstanding | 3.89% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -51.84% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | 63.52M USD |
| Diluted EPS (ttm) | 0.64 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.5M USD |
| Total Cash Per Share (mrq) | 0.03 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.314 |
| Book Value Per Share (mrq) | 0.053 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -4686000 USD |
| Levered Free Cash Flow (ttm) | -2755750 USD |
Profile of Galera Therapeutics
| Country | United States |
| State | PA |
| City | Malvern |
| Address | 101 Lindenwood Drive |
| ZIP | 19355 |
| Phone | 610 725 1500 |
| Website | https://www.galeratx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 3 |
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Q&A For Galera Therapeutics Stock
What is a current GRTX stock price?
Galera Therapeutics GRTX stock price today per share is 0.1 USD.
How to purchase Galera Therapeutics stock?
You can buy GRTX shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Galera Therapeutics?
The stock symbol or ticker of Galera Therapeutics is GRTX.
Which industry does the Galera Therapeutics company belong to?
The Galera Therapeutics industry is Biotechnology.
How many shares does Galera Therapeutics have in circulation?
The max supply of Galera Therapeutics shares is 203.27M.
What is Galera Therapeutics Price to Earnings Ratio (PE Ratio)?
Galera Therapeutics PE Ratio is 0.15625000 now.
What was Galera Therapeutics earnings per share over the trailing 12 months (TTM)?
Galera Therapeutics EPS is 0.64 USD over the trailing 12 months.
Which sector does the Galera Therapeutics company belong to?
The Galera Therapeutics sector is Healthcare.
Galera Therapeutics GRTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}